Rare Cancer Research Foundation

Our Pattern.org President Barbara Van Hare is joining OsteoBites this Thursday, June 4th at 3:00pm ET to discuss how patients have the power to contribute their resources to impact research. Without these types of donations, research can’t progress. Register for free here: https://www.eventbrite.com/e/osteobites-welcomes-barbara-vanhare-tickets-1989104649552

For decades, KRAS, the mutation driving more than 90% of pancreatic cancers, was considered undruggable. A Phase 3 trial of daraxonrasib just changed that, nearly doubling overall survival versus chemotherapy. Validating RAS as a therapeutic target opens the door to a next generation of even more selective inhibitors. This remarkable progress is the return on investment in basic science, exactly what RCRF is here to support. Shared data, biospecimens, and collaborative infrastructure make discoveries like this possible. Read more in this article from the New York Times (gift link).

How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it.